Long Term Real-World Outcomes of Trifluridine/Tipiracil in Metastatic Colorectal Cancer—A Single UK Centre Experience

por Tong, Daniel, Wang, Lei, Mendis, Jeewaka, Essapen, Sharadah
Publicado 2021

Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule t...

por Puvanenthiran, Soozana, Essapen, Sharadah, Seddon, Alan M., Modjtahedi, Helmout
Publicado 2016

Sister Mary Joseph's Nodule as a First Manifestation of Primary Peritoneal Cancer

por Iavazzo, C., Madhuri, K., Essapen, S., Akrivos, N., Tailor, A., Butler-Manuel, S.
Publicado 2012

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers

por Khelwatty, Said A, Essapen, Sharadah, Seddon, Alan M, Fan, Zhen, Modjtahedi, Helmout
Publicado 2015

The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal can...

por Khelwatty, Said, Essapen, Sharadah, Bagwan, Izhar, Green, Margaret, Seddon, Alan, Modjtahedi, Helmout
Publicado 2016

Co-Expression of HER Family Members in Patients with Dukes’ C and D Colon Cancer and Their Impacts on Patient Prognosis and Survival

por Khelwatty, Said Abdullah, Essapen, Sharadah, Bagwan, Izhar, Green, Margaret, Seddon, Alan Michael, Modjtahedi, Helmout
Publicado 2014

Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer

por Khelwatty, Said Abdullah, Essapen, Sharadah, Bagwan, Izhar, Green, Margaret, Seddon, Alan M., Modjtahedi, Helmout
Publicado 2019

HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer

por Khelwatty, Said A., Puvanenthiran, Soozana, Essapen, Sharadah, Bagwan, Izhar, Seddon, Alan M., Modjtahedi, Helmout
Publicado 2021

Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer

por Puvanenthiran, Soozana, Essapen, Sharadah, Haagsma, Ben, Bagwan, Izhar, Green, Margaret, Khelwatty, Said Abdullah, Seddon, Alan, Modjtahedi, Helmout
Publicado 2018

Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10

por Modjtahedi, H, Khelwatty, S A, Kirk, R S, Seddon, A M, Essapen, S, Del Vecchio, C A, Wong, A J, Eccles, S
Publicado 2012

Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations

por Gollins, Simon, West, Nick, Sebag-Montefiore, David, Myint, Arthur Sun, Saunders, Mark, Susnerwala, Shabbir, Quirke, Phil, Essapen, Sharadah, Samuel, Leslie, Sizer, Bruce, Worlding, Jane, Southward, Katie, Hemmings, Gemma, Tinkler-Hundal, Emma, Taylor, Morag, Bottomley, Daniel, Chambers, Philip, Lawrie, Emma, Lopes, Andre, Beare, Sandy
Publicado 2017

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

por Iveson, Timothy J, Kerr, Rachel S, Saunders, Mark P, Cassidy, Jim, Hollander, Niels Henrik, Tabernero, Josep, Haydon, Andrew, Glimelius, Bengt, Harkin, Andrea, Allan, Karen, McQueen, John, Scudder, Claire, Boyd, Kathleen Anne, Briggs, Andrew, Waterston, Ashita, Medley, Louise, Wilson, Charles, Ellis, Richard, Essapen, Sharadah, Dhadda, Amandeep S, Harrison, Mark, Falk, Stephen, Raouf, Sherif, Rees, Charlotte, Olesen, Rene K, Propper, David, Bridgewater, John, Azzabi, Ashraf, Farrugia, David, Webb, Andrew, Cunningham, David, Hickish, Tamas, Weaver, Andrew, Gollins, Simon, Wasan, Harpreet S, Paul, James
Publicado 2018

SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer

por Robles-Zurita, José, Boyd, Kathleen A., Briggs, Andrew H., Iveson, Timothy, Kerr, Rachel S., Saunders, Mark P., Cassidy, Jim, Hollander, Niels Henrik, Tabernero, Josep, Segelov, Eva, Glimelius, Bengt, Harkin, Andrea, Allan, Karen, McQueen, John, Pearson, Sarah, Waterston, Ashita, Medley, Louise, Wilson, Charles, Ellis, Richard, Essapen, Sharadah, Dhadda, Amandeep S., Hughes, Rob, Falk, Stephen, Raouf, Sherif, Rees, Charlotte, Olesen, Rene K, Propper, David, Bridgewater, John, Azzabi, Ashraf, Farrugia, David, Webb, Andrew, Cunningham, David, Hickish, Tamas, Weaver, Andrew, Gollins, Simon, Wasan, Harpreet S, Paul, James
Publicado 2018

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, random...

por Clamp, Andrew R, James, Elizabeth C, McNeish, Iain A, Dean, Andrew, Kim, Jae-Won, O'Donnell, Dearbhaile M, Gallardo-Rincon, Dolores, Blagden, Sarah, Brenton, James, Perren, Tim J, Sundar, Sudha, Lord, Rosemary, Dark, Graham, Hall, Marcia, Banerjee, Susana, Glasspool, Rosalind M, Hanna, C Louise, Williams, Sarah, Scatchard, Kate M, Nam, Helena, Essapen, Sharadah, Parkinson, Christine, McAvan, Lucy, Swart, Ann Marie, Popoola, Babasola, Schiavone, Francesca, Badrock, Jonathan, Fananapazir, Fuad, Cook, Adrian D, Parmar, Mahesh, Kaplan, Richard, Ledermann, Jonathan A
Publicado 2022